Handelsavisen
prelaunch
Companies Healthcare GAUD.NS
GA
GAUD.NS NSE (India) Healthcare Facilities & Services

Gaud.Ns

$107,83
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
37,6 %
ROE
41,3 %
Net margin
27,0 %
Debt / equity
0,45
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

GAUD.NS operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Business. GAUD.NS operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityBiotechnology
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
41,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning GAUD.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to GAUD.NS. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    GAUD.NS operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityBiotechnology
    AI synthesis
    GENERATED

    GAUD.NS maintains a relatively strong liquidity position, with a current ratio of 1.42, indicating that it has sufficient current assets to cover its current liabilities. However, the company's liquidity is assessed as medium, and it has a negative net cash position after subtracting total debt, which could pose a challenge in the short term.

    In terms of profitability, GAUD.NS demonstrates a return on equity (ROE) of 41.31% and a return on assets (ROA) of 21.61%, both of which are strong indicators of efficient use of equity and assets to generate profit. These figures suggest that the company is performing well compared to the industry median for healthcare facilities and services, where ROE and ROA are typically lower due to the capital-intensive nature of the sector.

    The company's revenue is not segmented by geographic regions or business lines in the provided data, making it difficult to assess the concentration of revenue across different markets or product lines. However, the absence of detailed segment data implies that the company may not have a highly diversified revenue base, which could increase its exposure to regional or market-specific risks.

    GAUD.NS has shown a positive growth trajectory, with a strong operating cash flow of INR 87,176,000 and a free cash flow of INR 122,959,000, indicating that the company is generating more cash than it is spending on operations and capital expenditures. The capital expenditure of INR -88,784,000 suggests that the company is investing in its operations, which could support future growth.

    The risk assessment for GAUD.NS indicates a medium liquidity risk and a low dilution risk. The company's debt-to-equity ratio of 0.45 is relatively low, suggesting that it is not overly leveraged. However, the negative net cash position after subtracting total debt is a concern, as it may limit the company's ability to fund operations or investments without external financing.

    There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The absence of recent events does not necessarily indicate a lack of activity but may reflect the timing of the data collection.

    Key takeaways
    • GAUD.NS has a strong return on equity and return on assets, indicating efficient use of capital.
    • The company's liquidity is assessed as medium, with a current ratio of 1.42.
    • GAUD.NS has a negative net cash position after subtracting total debt, which could pose a short-term liquidity challenge.
    • The company is generating positive operating and free cash flows, supporting its growth and operational needs.
    • The absence of detailed segment data suggests a potential lack of revenue diversification.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $107,83
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $463.0M
    Net cash
    -$206.1M
    Current ratio
    1.4
    Debt / equity
    0.5
    ROA
    21.6%
    ROE
    41.3%
    Cash conversion
    46.0%
    CapEx / revenue
    -12.6%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin37,6 %Best in class
    Net Margin27,1 %Best in class
    ROE41,3 %Best in class
    Capex / Rev-12,6 %Below median
    D/E0,45Below median
    Cash Conv0,46Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • GAUD.NS Market data — financials · 2026-05-28

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    150shares short-6.2% vs prior
    12.5days to cover
    100.0%short of daily vol
    9fails-to-deliver
    as of 2026-06-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    GAUD.NSCanonical
    NSE (India) · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage